Our CEO, Hendrik Dietz aligned with the editorial team at The Medicine Maker to offer his view on “Making CAR T Truly Off the Shelf”. He explores how a single infusion can transform a patient’s own T cells into cancer-fighting machines using single-stranded DNA (ssDNA) and lipid nanoparticles. This approach overcomes the existing hurdles of innate immune activation and inefficient nuclear entry that have slowed down the progress of CAR-T therapies.
Read more to learn how ssDNA can be used both for transient expression and permanent genetic CAR integration to engineer fit-for-purpose therapies and make in vivo CAR-T a scalable reality.